Loading…
Kairos Pharma, Ltd. is projected to decline to $0.3253 by 2027, a -8% move from its current price of $0.3527. KAPA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.3398 | $0.3528 | $0.3663 | +0.04% |
| Jul 13 | $0.3347 | $0.353 | $0.3722 | +0.08% |
| Jul 14 | $0.3309 | $0.3531 | $0.3768 | +0.12% |
| Jul 15 | $0.3277 | $0.3533 | $0.3808 | +0.16% |
| Jul 16 | $0.325 | $0.3534 | $0.3843 | +0.20% |
| Jul 17 | $0.3225 | $0.3535 | $0.3876 | +0.24% |
| Jul 18 | $0.3203 | $0.3537 | $0.3906 | +0.28% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.3203 | $0.3537 | $0.3906 | +0.28% |
| Week 2 | $0.3082 | $0.3547 | $0.4082 | +0.56% |
| Week 3 | $0.2995 | $0.3557 | $0.4224 | +0.85% |
| Week 4 | $0.2924 | $0.3567 | $0.435 | +1.13% |
| Week 5 | $0.2865 | $0.3577 | $0.4466 | +1.41% |
| Week 6 | $0.2812 | $0.3587 | $0.4575 | +1.70% |
| Week 7 | $0.2766 | $0.3597 | $0.4678 | +1.98% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company focused on immunotherapy and cell therapies for cancer. The company offers therapeutics including antibodies and small molecules for prostate cancer, lung cancer, breast cancer, and glioblastoma, and it has ENV 105 in Phase 2 for prostate cancer patients resistant to androgen-targeted therapy and in Phase 1 for non-small cell lung cancer.
Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California. It was formerly NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016.
Kairos Pharma, Ltd. trades under the symbol KAPA in the Healthcare sector. Its current price is $0.3748 and its market cap is $8.02M, with a rank of 5172. The year-by-year forecast presents a mixed near-term view but shows growth potential in the longer term, including bullish readings in the 2032, 2033, 2040, and 2050 periods.
The average price path rises from around the mid-$0.3s to roughly $0.938 in 2050, with a max forecast reaching up to $1.93 in that year and corresponding ROI figures up to 150.3.
A major floor 33.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.8% away) — a key level to hold.
The nearest ceiling, 49.4% above — a clean break opens room to run.
A major ceiling 94.2% above — clearing it would confirm fresh momentum.
Key KAPA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of KAPA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.3662 | Sell | $0.3636 | Sell |
| MA 10 | $0.366 | Sell | $0.3732 | Sell |
| MA 20 | $0.3992 | Sell | $0.3962 | Sell |
| MA 50 | $0.4638 | Sell | $0.4561 | Sell |
| MA 100 | $0.5333 | Sell | $0.5372 | Sell |
| MA 200 | $0.7119 | Sell | $0.6839 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.97 | Neutral |
| Stoch RSI (14) | 68.08 | Neutral |
| CCI (20) | -86.47 | Neutral |
| Williams %R (14) | -96.30 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -17.33 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 3.70 | Buy |
| TRIX (15) | -1.04 | Sell |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 32.73 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -60.00 | Sell |
| Hull MA (9) | 0.36 | Sell |
| ADX (14) | 28.39 | Sell |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is currently NEUTRAL. RSI14 is 30 and the moving averages are $0.5159 for SMA50 and $0.7734 for SMA200. Near-term support stands at $0.375 and resistance at $0.553. The 30-day price range spans from $0.2961 to $0.4745, and the stock exhibits an annualized volatility of 70%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.35 | $0.3527 | $0.4642 | 0% | Neutral | |
| $0.25 | $0.3253 | $0.4529 | -8% | Neutral | |
| $0.2382 | $0.3226 | $0.4714 | -9% | Neutral | |
| $0.2252 | $0.3154 | $0.4784 | -11% | Neutral | |
| $0.2383 | $0.3439 | $0.5381 | -2% | Neutral | |
| $0.2744 | $0.4069 | $0.6542 | +15% | Neutral | |
| $0.278 | $0.4232 | $0.6969 | +20% | Neutral | |
| $0.2937 | $0.4581 | $0.7709 | +30% | Bullish | |
| $0.2683 | $0.4283 | $0.7353 | +21% | Bullish | |
| $0.2313 | $0.3776 | $0.6603 | +7% | Neutral | |
| $0.3158 | $0.5724 | $1.08 | +62% | Bullish | |
| $0.3904 | $0.8561 | $1.80 | +143% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.35 | $0.3527 | $0.419 | +0.00% |
| August 2026 | $0.2911 | $0.3471 | $0.4276 | -1.58% |
| September 2026 | $0.3038 | $0.3658 | $0.4575 | +5.39% |
| October 2026 | $0.307 | $0.3728 | $0.472 | +1.90% |
| November 2026 | $0.2943 | $0.3599 | $0.4605 | -3.46% |
| December 2026 | $0.2919 | $0.3593 | $0.4642 | -0.15% |
Click any year to see its month-by-month KAPA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Kairos Pharma, Ltd.'s 2026 outlook centres on $0.3527, within a $0.35 to $0.4642 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, KAPA could reach as high as $0.4529, with a base case around $0.3253 and support toward $0.25 — roughly -8% from $0.3527. A consolidation phase looks the most probable path here.
Expect KAPA to range from $0.2382 to $0.4714 through 2028. The $0.3226 average target implies a -9% move from current prices. That is -1% versus the projected 2027 average. Price action looks broadly range-bound.
The KAPA price prediction for 2029 points to an average of $0.3154 (low $0.2252, high $0.4784) — a potential decline of -11% on today's $0.3527. A consolidation phase looks the most probable path here.
In 2030, KAPA is projected to trade between $0.2383 and $0.5381, averaging $0.3439 — a potential decline of -2% from today's $0.3527. That is up +9% on the projected 2029 average. Price action looks broadly range-bound.
Kairos Pharma, Ltd.'s 2031 outlook centres on $0.4069, within a $0.2744 to $0.6542 range. That is up +18% on the projected 2030 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, KAPA could reach as high as $0.6969, with a base case around $0.4232 and support toward $0.278 — roughly +20% from $0.3527. Price action looks broadly range-bound.
Expect KAPA to range from $0.2937 to $0.7709 through 2033. The $0.4581 average target implies a +30% move from current prices. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The KAPA price prediction for 2034 points to an average of $0.4283 (low $0.2683, high $0.7353) — a potential gain of +21% on today's $0.3527. Momentum favours further upside here.
In 2035, KAPA is projected to trade between $0.2313 and $0.6603, averaging $0.3776 — a potential gain of +7% from today's $0.3527. That is -12% versus the projected 2034 average. A consolidation phase looks the most probable path here.
Kairos Pharma, Ltd.'s 2040 outlook centres on $0.5724, within a $0.3158 to $1.08 range. That is up +52% on the projected 2035 average. That marks a +62% change versus current levels. Momentum favours further upside here.
By 2050, KAPA could reach as high as $1.80, with a base case around $0.8561 and support toward $0.3904 — roughly +143% from $0.3527. Buyers look set to stay in control over this stretch.
Investing $1,000 in KAPA today (≈ 2,835.270768 KAPA) could be worth
$2,427.18
+$1,427.18 (+143%) by 2050 · US Dollar
Based on the average projected KAPA price of $0.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in KAPAwould be worth at today's price.
$1,000 invested in KAPA on Jul 10, 2025 (≈ 1,406.469711 KAPA) would be worth
$496.06
-$503.94 (-50.4%) today · 0.50× · US Dollar
Based on a KAPA entry price of $0.711 vs. today's $0.3527.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.37 | $953.24 | -4.7% |
| 1 month ago | $0.43 | $820.23 | -18.0% |
| 3 months ago | $0.583 | $604.97 | -39.5% |
| 6 months ago | $0.88 | $400.8 | -59.9% |
| 1 year ago | $0.711 | $496.06 | -50.4% |
| All time (1.8y) ago | $2.6 | $135.65 | -86.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our KAPA forecast.
Our base-case forecast reaches $0.71 around 2050.
Implied market cap at $0.71: $15.2M
The multi-year forecast shows a largely flat to slightly rising start through 2026-2029, with 2026 min $0.3748, avg $0.3748, max $0.4998 and ROI 0. In 2027-2029, the avg moves toward the low to mid $0.3s with negative ROIs of -8.4 to -6.8. From 2030 onward, the path broadens: 2030 min $0.2551, avg $0.3642, max $0.5636 with ROI -2.8; 2031 min $0.295, avg $0.4322, max $0.6864 with ROI 15.3.
The years 2032 and 2033 turn bullish, with avg $0.4642 and $0.4781 and max values up to $0.7545 and $0.7936, and ROIs of 23.8 and 27.6 respectively. In 2040 the forecast strengthens to avg $0.611 and max $1.13 with ROI 63 and sentiment BULLISH, and by 2050 the avg is $0.938 with a max of $1.93, min $0.4455, and ROI 150.3, supported by a BULLISH stance.
Tap a question to reveal the answer.
2030 min $0.2551, avg $0.3642, max $0.5636; ROI -2.8; Sentiment NEUTRAL.
The forecast shows NEUTRAL in the near term and BULLISH in later years, with 2031 avg $0.4322 and ROI 15.3; 2032 avg $0.4642 and ROI 23.8; 2033 avg $0.4781 and ROI 27.6; 2040 avg $0.611 and ROI 63; 2050 avg $0.938 and ROI 150.3.
Yes—the max forecast for 2050 is $1.93, which exceeds $1.
2027 min $0.2649, avg $0.3432, max $0.4752; 2028 min $0.2538, avg $0.3414, max $0.4948; 2029 min $0.2516, avg $0.3492, max $0.5246; 2030 min $0.2551, avg $0.3642, max $0.5636.
Current price $0.3748; Market cap $8.02M; Rank 5172.
Kairos Pharma, Ltd. Community Discussion
0Share your Kairos Pharma, Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.